AbbVie updates Q4 and FY 2023 adjusted EPS guidance for $282M IPR&D expense

AbbVie Inc.

2023-FY EPS reported $2.72 revenue$54,318,000,000

Q4 2023 acquired IPR&D and milestones expense of $282M pre-tax reduces GAAP and adjusted EPS by $0.15.
Updated Q4 2023 adjusted diluted EPS guidance range: $2.72 - $2.76 (prior $2.87 - $2.91).
Full-year 2023 adjusted diluted EPS guidance now $11.04 - $11.08 (prior $11.19 - $11.23).
Full-year 2023 acquired IPR&D and milestones expense totals $778M.
AbbVie notes these expenses are inherently unforecastable; final Q4 results may differ.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbbVie Inc. reported full-year ended December 31, 2023 results: EPS $11.04 - $11.08. Guidance reaffirmed.

Period: full-year ended December 31, 2023
EPS: $11.04 - $11.08
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

AbbVie’s full-year 2023 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2023 acquired IPR&D and milestones expense, is $11.04 - $11.08.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbbVie Inc. reported quarter ended December 31, 2023 results: EPS $2.72 - $2.76. Guidance reaffirmed.

Period: quarter ended December 31, 2023
EPS: $2.72 - $2.76
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

AbbVie’s fourth quarter 2023 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2023 acquired IPR&D and milestones expense, is $2.72 - $2.76.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001551152-24-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.